~~<i id='904F3F0987'><strike id='904F3F0987'><tt id='904F3F0987'><pre id='904F3F0987'></pre></tt></strike></i>~~

Home» Wikipedia» comprehensive

comprehensive

author：Wikipedia 2025-09-29 04:54:01 Page View：1

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Study: Adult vaccinations pay for themselves in societal benefits
Next article： Jerome Adams on the need for new antivirals for Covid

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

Software glitch causes Tandem insulin pump to shutdown, FDA warns

AdobeAtleast224diabetespatientshavebeenharmedbyasoftwareerrorcausingtheirinsulinpumpstospontaneously

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

What nurses really want: sufficient staffing for patient care

AdobePizza.Coloringbooks.Goodybags.Theycouldbeactivitiesata5-year-old’sbirthdayparty.Butthey’renot:T